12 January 2021 : Original article
Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus
Shun Nishioka1ABCDE, Takeshi Ishimura1ACDE*, Takahito Endo1B, Naoki Yokoyama1BC, Satoshi Ogawa1BCD, Masato Fujisawa1EDOI: 10.12659/AOT.926476
Ann Transplant 2021; 26:e926476
Table 2 Univariate and multivariate analysis of the parameters predicting the progression of the graft fibrosis (ΔFI >10%).
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| P value | Odds ratio | 95% CI | P value | |
| EVR early add-on (yes no) | <0.01 | 0.036 | 0.0029–0.44 | <0.01 |
| Recipient age, years (≤50 >50) | 0.20 | |||
| Donor age, years (≤50 >50) | 0.34 | |||
| Donor type (living-related deceased) | 0.078 | |||
| CIT, minutes (≤100 >100) | 0.035 | 0.36 | 0.054–2.4 | 0.29 |
| BMI (≤25 >25) | 0.88 | |||
| Pre-KTx dialysis period, days(≤1000 >1000) | 0.014 | 0.25 | 0.060–1.0 | 0.052 |
| HLA mismatch(0–3 4–6) | 0.60 | |||
| DM (− +) | 0.28 | |||
| HT (≤sBP 140 mmHg >140 mmHg) | 0.16 | |||
| LDL-chol (≤140 mg/dl >140 mg/dl) | 0.49 | |||
| Triglyceride (≤150 mg/dl >150 mg/dl) | 0.41 | |||
| eGFR at 3months after KTx, ml/min/1.73 m (≤60 >60) | 0.44 | |||
| Tac C at 1year after KTx, ng/ml (≤5 >5) | 0.011 | 0.33 | 0.065–1.7 | 0.26 |
| Tac C at 3year after KTx, ng/ml (≤5 >5) | 0.11 | |||
| ΔFI=FI at 3 years after KTx–FI at 3 months after KTx; FI – fibrosis index; EVR – everolimus; CIT – cold ischemic time; BMI – body mass index; KTx – kidney transplantation; HLA – human leukocyte antigen; DM – diabetes mellitus; HT – hypertension; sBP – systolic blood pressure; LDL – low density lipoprotein; eGFR – estimated glomerular filtration rate; Tac – tacrolimus; C – trough concentration. | ||||